67 studies on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 20,061 published Retatrutide COA source records from third-party laboratories, covering 2,698 publicly attributable vendor identities. Across 18,418 records with positive numeric purity, the arithmetic mean is 99.66%. 319 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 55 positive purity results are below 90%; 1,051 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $10.12 | $8.00–$13.00 | $2.02 | 4 sources · 4 offers |
| 10 mg | $12.33 | $10.50–$14.50 | $1.23 | 3 sources · 3 offers |
| 15 mg | $18.62 | $14.50–$26.00 | $1.24 | 4 sources · 4 offers |
| 20 mg | $23.25 | $17.50–$32.50 | $1.16 | 4 sources · 4 offers |
| 30 mg | $29.30 | $21.50–$39.00 | $0.98 | 5 sources · 5 offers |
| 40 mg | $35.00 | $28.00–$45.50 | $0.88 | 4 sources · 4 offers |
| 50 mg | $41.88 | $32.00–$52.00 | $0.84 | 4 sources · 4 offers |
| 60 mg | $39.83 | $35.00–$45.50 | $0.66 | 3 sources · 3 offers |
| 120 mg | $54.50 | $54.50–$54.50 | $0.45 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T04:28:59.768141+00:00. Calculation time is not a laboratory observation date.
Within that total, 5479 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 157 | 99.69% | 0 of 137 (0.0%) 0 0% / not detected · 0 wrong compound · 20 unclassified | Reveal with Pro → | |
| #2 | 130 | 99.64% | 0 of 129 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 151 | 99.44% | 0 of 127 (0.0%) 0 0% / not detected · 0 wrong compound · 24 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120445 (99.75%) · #120444 (99.86%) · #120417 (99.83%) · #120392 (99.86%) · #120391 (99.85%) · #120307 (99.79%)
**GLP-1 receptor agonists are now a validated pharmacological option for adolescents with obesity**, offering significant weight loss and metabolic improvements beyond lifestyle interventions alone. For biohackers and…
This comprehensive meta-analysis provides critical guidance for individuals and clinicians navigating pharmacologic options for **weight management**. **Semaglutide** and **tirzepatide** are strongly affirmed as leadi…
Emerging anti-obesity pharmacotherapies and multimodal strategies offer new avenues for treating obstructive sleep apnea, moving beyond traditional CPAP.
This review examines the therapeutic potential of GLP-1 Receptor Agonists in **Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)**, highlighting their impact on both liver and cardiovascular health.
This review underscores a paradigm shift in **obesity management**, moving beyond mere appetite suppression to integrated central-peripheral strategies. For peptide users and clinicians, this means future protocols wi…
**Expanded access** to investigational drugs like **Retatrutide** (LY3437943) provides a critical pathway for patients facing serious or immediately life-threatening conditions who have exhausted all approved treatmen…
This clinical guide is highly relevant for peptide users, biohackers, and clinicians as it addresses the evolving role of `GLP-1 RAs` beyond traditional disease management, particularly for **elective health optimizat…
This new synthesis method could significantly impact the manufacturing landscape for Retatrutide and other complex therapeutic peptides. **By offering a more practical and flexible alternative to SPPS, this LPPS appro…
This review provides a crucial framework for understanding the potential challenges of performing autologous fat grafting in patients on GLP-1 RAs. **Clinicians should consider the potential for reduced fat graft surv…
GLP-1-based and multiagonist obesity therapies demonstrate significant multisystem benefits across metabolic, cardiovascular, and neuropsychiatric conditions, often independent of weight loss.
Review outlines the rapidly expanding therapeutic landscape for **diabetic kidney disease (DKD)**, integrating novel drug classes with proven kidney and cardiovascular benefits.
This review underscores the growing importance of **incretin receptor agonists** as a therapeutic cornerstone for individuals with **MASLD**, particularly those with co-existing **type 2 diabetes** or **obesity**. For…
A narrative review explores the pathophysiological links between **Diabetes Mellitus** and stroke, examining the potential of `GLP-1 RAs` and `GLP-1/GIP RAs` for prevention and management.
This review underscores a pivotal shift in how **heart failure with preserved or mildly reduced ejection fraction** (HFpEF/HFmrEF) might be managed, moving beyond symptomatic relief to targeting underlying metabolic a…
The development of **effective oral GLP-1 therapies could significantly broaden patient access and adherence**, overcoming the limitations of injectable formulations like injection aversion and cold-chain requirements…
Incretin receptor agonists (GLP-1, GLP-1/GIP, GLP-1/GIP/glucagon) show promise for **MASLD**, reducing steatosis, inflammation, and fibrosis by targeting metabolic dysfunction.
This review underscores a significant shift in how **diabetes mellitus** and **stroke** risk are managed, highlighting the expanded utility of incretin-based therapies beyond glycemic control. For clinicians and indiv…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
This trial is crucial because retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, holds significant promise for treating obesity and its complex comorbidities. If successful, it could off…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The successful modulation of calorie intake and energy expenditure by LY3437943 could represent a significant advancement in obesity treatment. If LY3437943 demonstrates a favorable impact on these parameters, it coul…
If successful, this study could demonstrate a significant cardio-renal protective effect of Retatrutide beyond its known weight-loss benefits. This would be a crucial advancement, as current treatments for obesity oft…
The SYNERGY-OUTCOMES study holds immense significance as it addresses a critical unmet medical need for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition without approved pharmacologic trea…
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The e…
A favorable drug-drug interaction profile is a critical factor for the successful development of any new medication, particularly for chronic conditions like obesity where patients often take multiple concomitant drug…
This Phase 3b trial is pivotal for optimizing Retatrutide's clinical utility by identifying the most effective and well-tolerated dosing strategies for long-term use. Understanding the nuances of dose escalation can s…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
Free, no account — handy when you're working with Retatrutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account